von Willebrand disease: proposing definitions for future research

• Type of Material: Article
• Authors: Nathan T. Connell, Harvard University; Paula D. James, Queens University; Romina Brignardello-Petersen, McMaster University; Rezan Abdul-Kadir, University College London; Barbara Ameer, Pharmacol Consulting; Alice Arapshian, Independent; Susie Couper, Independent; Jorge Di Paola, Washington University; Jeroen Eikenboom, Leiden University Medical Center; Nicolas Giraud, Independent; Jean M. Grow, Marquette University; Sandra Haberichter, Versiti Blood Research Institute; Vicki Jacobs-Pratt, Independent; Barbara A. Konkle, Bloodworks Northwest; Peter Kouides, University of Rochester; Michael Laffan, Imperial College London; Michelle Lavin, Royal College of Surgeons in Ireland; Frank W. G. Leebeek, Erasmus Medical Center; Claire McLintock, Auckland City Hospital; Simon McRae, Launceston General Hospital; Robert Montgomery, Medical College of Wisconsin; Sarah O'Brien, Ohio State College of Medicine; James S. O'Donnell, Royal College of Surgeons in Ireland; Margareth C. Ozelo, University of Campinas; Nikole Scappe, Independent; Robert Sidonio Jr, Emory University; Alberto Tosetto, S. Bortolo Hospital; Angela C. Weyand, University of Michigan; Mohamad A. Kalot, University of Kansas; Nedaa Husainat, University of Kansas; Reem A. Mustafa, University of Kansas; Veronica H. Flood, Medical College of Wisconsin
• Language: English
• Date: 2021-01-26
• Publisher: Elsevier
• Publication Version: Final Published Version
• Copyright Statement: © 2021 by The American Society of Hematology
• Final Published Version (URL): http://dx.doi.org/10.1182/bloodadvances.2020003620
• Title of Journal or Parent Work: Blood Advances
• Volume: 5
• Issue: 2
• Start Page: 565
• End Page: 569
• Grant/Funding Information: None declared
• Keywords: Efficacy; Hematology; Phenotype; Science & Technology; Desmopressin; Concentrate wilate(R); WFH 2021 guidelines; Biologic response; Life Sciences & Biomedicine; Factor-VIII; Blood loss; Management; Children
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Oncology; Health Sciences, Immunology

Abstract

von Willebrand disease (VWD) is a common bleeding disorder, which affects 1 in 100 individuals based on laboratory testing and at least 1 in 1000 individuals based on presence of abnormal bleeding symptoms.1,2 VWD was first described almost 100 years ago, and since the initial report, major advances in both diagnostic testing and treatment options have improved outcomes for patients living with VWD; however, many patients still experience significant complications and barriers to treatment. An underlying problem is the lack of consistent unified definitions.